Paxlovid (nirmatrelvir/ritonavir) is an antiviral drug used to treat COVID-19, nirmatrelvir, a
SARS-CoV-2 main protease inhibitor, works by inhibiting viral replication in the early stages …

Background Drug-drug interaction management is complex. Nirmatrelvir/ritonavir is a potent
cytochrome P450 (CYP) 3A inhibitor and influences pharmacokinetics of co-administered …

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has
had a significant impact on communities and health systems. New antiviral medications …

Nirmatrelvir is an orally administered anti-SARS-CoV-2 drug used in combination with
ritonavir, the drug-metabolizing cytochrome P450 (CYP) 3A inhibitor, to evade metabolism …

Background Nirmatrelvir/ritonavir, a newly authorized drug for the treatment of COVID-19, is
a strong CYP3A4 inhibitor that can interact with many drugs, such as tacrolimus, reducing its …

Introduction The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or
COVID-19) pandemic has had a significant impact on communities and health systems. The …

Nirmatrelvir/ritonavir was recently granted emergency use authorization for mild to moderate
coronavirus disease 2019. Drug–drug interactions between ritonavir and tacrolimus are …

To the Editor: A 41-year-old female patient with a history of renal transplant presented to the
emergency department with nausea, vomiting, and tremors. The patient had been …

Background Paxlovid (nirmatrelvir/ritonavir) is a novel drug available under emergency use
authorization by the Food and Drug Administration for the treatment of COVID-19 infection …

Tacrolimus is commonly used as a prophylactic against acute rejection in transplant
patients. Tacrolimus toxicity has numerous presentations that have been well documented in …